CD4-induced activation in a soluble HIV-1 Env trimer (scientific article)

Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Q53851964

Escherichia coli expression, purification, and biological activity of a truncated soluble CD4.

Q54715165

Quantitative mapping of glycoprotein micro-heterogeneity and macro-heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides

Q63342125

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation

Q21131394

Energetics of the HIV gp120-CD4 binding reaction

Q22254716

Structural mass spectrometry of proteins using hydroxyl radical based protein footprinting

Q24635319

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Q27644478

Molecular architecture of native HIV-1 gp120 trimers

Q27651385

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

Q27658989

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Q27675032

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

Q27677104

Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops

Q27678226

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

Q27678312

Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy

Q27680442

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

Q27680496

Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

Q27680497

Core structure of gp41 from the HIV envelope glycoprotein

Q27736064

UCSF Chimera--a visualization system for exploratory research and analysis

Q27860666

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

Q28131812

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells

Q28288205

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies

Q28299280

Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein

Q28646759

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Q29547347

Broad neutralization coverage of HIV by multiple highly potent antibodies

Q29615361

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

Q29619017

Secondary reactions and strategies to improve quantitative protein footprinting.

Q30350704

Solution Structure, Conformational Dynamics, and CD4-Induced Activation in Full-Length, Glycosylated, Monomeric HIV gp120

Q30524225

Semi-automated data processing of hydrogen exchange mass spectra using HX-Express

Q31056778

Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility

Q33323199

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Q33636347

Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions

Q33789251

Hydrogen exchange mass spectrometry: what is it and what can it tell us?

Q33847013

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

Q33937285

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins

Q34332728

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Q34341843

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Q34361680

Fast Photochemical Oxidation of Proteins and Mass Spectrometry Follow Submillisecond Protein Folding at the Amino-Acid Level

Q34449755

Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120

Q34885869

Modification site localization scoring integrated into a search engine.

Q35098560

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures

Q35105223

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

Q35978823

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

Q36525116

The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions.

Q36607016

Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

Q36649958

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Q36692987

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

Q36802333

Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

Q36824891

Hydroxyl radical-mediated modification of proteins as probes for structural proteomics

Q36903727

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

Q37010292

Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers

Q37123501

A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.

Q37252789

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation

Q37318042

Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra

Q37373776

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

Q37415987

Tracking hydrogen/deuterium exchange at glycan sites in glycoproteins by mass spectrometry

Q38602533

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

Q39588870

P433

issue

P304

page(s)

974-984

P577

publication date

2014-06-12

P1433

published in

Structure

Q15709970

P1476

title

CD4-induced activation in a soluble HIV-1 Env trimer

P478

volume

Reverse relations

cites work (P2860)

Q35925858	A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS
Q54237723	A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers
Q38955459	A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry
Q36100426	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
Q28256508	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env
Q34870033	Applications of hydrogen/deuterium exchange MS from 2012 to 2014.
Q59354834	Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies
Q92718969	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
Q61815651	CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity
Q38753943	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Q36434196	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
Q29306052	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein
Q27303608	Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State
Q47551840	Computational study of HIV gp120 as a target for polyanionic entry inhibitors: Exploiting the V3 loop region.
Q26782237	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1
Q92719597	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
Q39949085	Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer
Q27644383	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
Q40076760	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Q41464728	Curcumin Increases HSP70 Expression in Primary Rat Cortical Neuronal Apoptosis Induced by gp120 V3 Loop Peptide
Q36102994	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens
Q58747611	Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer
Q26772129	Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion
Q61797839	Effects of CD4 Binding on Conformational Dynamics, Molecular Motions, and Thermodynamics of HIV-1 gp120
Q37300461	Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates
Q34869927	Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication
Q40276435	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.
Q53068939	Global site-specific analysis of glycoprotein N-glycan processing.
Q40058876	Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.
Q33753573	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies
Q39365785	HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike
Q28647225	HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers
Q38665463	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Q37055800	HIV-host interactome revealed directly from infected cells
Q41870119	Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
Q28271300	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes
Q38635401	Immunotherapeutic Approaches for the Control and Eradication of HIV.
Q40073525	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization
Q41447893	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers
Q38323609	Insights into the trimeric HIV-1 envelope glycoprotein structure
Q30383692	Isotope Labeling of Biomolecules: Structural Analysis of Viruses by HDX-MS.
Q52569620	Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.
Q54246851	Mapping mutational effects along the evolutionary landscape of HIV envelope
Q37240035	Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding
Q41341684	Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy
Q53695792	Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11.
Q36086357	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity
Q37633417	Native-like Env trimers as a platform for HIV-1 vaccine design
Q47562235	Neutralization tiers of HIV-1.
Q40125807	Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike
Q35835515	Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
Q64983102	Protein and Glycan Mimicry in HIV Vaccine Design.
Q64228820	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers
Q47313525	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers
Q30490942	Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
Q34831341	Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure
Q28263063	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers
Q27640572	Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection
Q39211319	Structural principles controlling HIV envelope glycosylation
Q52338073	Structure and Immune Recognition of the HIV Glycan Shield
Q35142291	Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
Q46631754	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.
Q27644634	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Q42207296	The HIV-1 Env trimer in HD.
Q64062464	Transient opening of trimeric prefusion RSV F proteins
Q27704710	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Q36791814	Tuning a High Transmission Ion Guide to Prevent Gas-Phase Proton Exchange During H/D Exchange MS Analysis

P356	DOI	10.1016/J.STR.2014.05.001
P932	PMC publication ID	4231881
P698	PubMed publication ID	24931470